METHODS: A total of 50 ART Adherent patients newly started/substituted on Tenofovir/Lamivudine/Dolutegravir were randomly selected from (St. Charles Borromeo Hospital and Holy Rosary Hospital). A total of 25 men of 30 years and above and 25 menopausal women of 50 years and above were sampled randomly from both hospitals with informed consent. Each of the 50 patients were placed on one month (TDF/3TC/DTG) with adequate counselling and monitoring. The daily dose of (TDF/3TC/DTG) were directed to be taken once in the morning after meal. Patient's were advised not to take the ART combination together with any drug or supplement. They were all accessed for adverse drug reactions on their next visit.

RESULTS: Statistical documentations of the different ADR's among patients, using the pharmacovigilance ADR's reporting form were recorded. 7 men representing 28% presented with CNS side-effects (Insomnia, headache, fatique and dizziness), 9 men representing 36% presented with GIT side-effects (Increased appetite, diarrhoea, nausea and vomiting). 2 men representing 8% presented with frequent urination, while 7 men representing 28% didn't come up with any significant ADR. 13 women representing 52% presented with GIT side-effects (Abdominal discomfort and pain, diarrhoea) while 6 women representing 24% presented with CNS side-effects (Fatique, headache, insomnia and dizziness), another 6 women representing 24% didn't come up with any significant ADR. A total of 13 patients of both men and women representing 26% of all presented with mild CNS ADR's, while a total of 22 patients representing 44% of all presented with moderate GIT ADR's. Finally, a total of 2 men only representing 4% of all presented with severe renal ADR's (Frequent urination).

CONCLUSIONS: The general ADR observed in combination of (TDF/3TC/DTG) is minimal and well separated. ADR's in (TDF/3TC/DTG) is better manage with most positive outcomes.